Learn More About Our Multiple Myeloma Cancer Trials

• 1 54767414SMM3001 Show More

  54767414SMM3001 – A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma.

  1. WHAT TYPE OF CANCER? WHAT STAGE?
  Smoldering Multiple Myeloma.

  2. WHO IS ELIGIBLE?
  Diagnosed within 5 years.

  3. HOW WILL I BE TREATED?
  Daratumumab (an anti-body-based drug, directed against CD38).

  For Physicians: More information about this specific trial at clinicaltrials.gov